Increased CD36 expression signals monocyte activation among patients with type 2 diabetes

Yijuan Sun; Marina Scavini; Robert A. Orlando; Glen H. Murata; Karen S. Servilla; Antonios H. Tzamaloukas; Ronald Schrader; Edward J. Bedrick; Mark R. Burge; Nada A. Abumrad; Philip G. Zager

doi:10.2337/dc10-0460

Increased CD36 expression signals monocyte activation among patients with type 2 diabetes

Yijuan Sun, Marina Scavini, Robert A. Orlando, Glen H. Murata, Karen S. Servilla, Antonios H. Tzamaloukas, Ronald Schrader, Edward J. Bedrick, Mark R. Burge, Nada A. Abumrad, Philip G. Zager

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

OBJECTIVE - To explore the hypothesis that CD36, a scavenger receptor and fatty acid translocase, is upregulated in peripheral blood mononuclear cells (PBMCs) among patients with type 2 diabetes and is a biomarker of PBMC activation and inflammation. RESEARCH DESIGN AND METHODS - We used a cross-sectional observational design to study a multi-racial/ethnic population sample consisting of Caucasians, Hispanics, and Native Americans with type 2 diabetes (n = 33) and nondiabetic control subjects (n = 27). PBMC CD36 mRNA/protein and plasma high sensitivity (hs) C-reactive protein (hsCRP), hs-interleukin-6 (hsIL-6), and adiponectin were measured. RESULTS - Unadjusted PBMC CD36 mRNA and protein were 1.56- and 1.63-fold higher, respectively, among type 2 diabetic subjects versus control subjects. PBMC CD36 protein was directly associated with CD36 mRNA, plasma hsCRP, and hsIL-6 and inversely associated with plasma adiponectin in both groups. CONCLUSIONS - Increased CD36 expression is a biomarker of PBMC activation and inflammation and may become a useful tool in cardiovascular disease risk stratification.

Original language	English (US)
Pages (from-to)	2065-2067
Number of pages	3
Journal	Diabetes care
Volume	33
Issue number	9
DOIs	https://doi.org/10.2337/dc10-0460
State	Published - Sep 2010
Externally published	Yes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc10-0460

Cite this

@article{2a62add90bde41a6a89c82e0131b37bd,

title = "Increased CD36 expression signals monocyte activation among patients with type 2 diabetes",

abstract = "OBJECTIVE - To explore the hypothesis that CD36, a scavenger receptor and fatty acid translocase, is upregulated in peripheral blood mononuclear cells (PBMCs) among patients with type 2 diabetes and is a biomarker of PBMC activation and inflammation. RESEARCH DESIGN AND METHODS - We used a cross-sectional observational design to study a multi-racial/ethnic population sample consisting of Caucasians, Hispanics, and Native Americans with type 2 diabetes (n = 33) and nondiabetic control subjects (n = 27). PBMC CD36 mRNA/protein and plasma high sensitivity (hs) C-reactive protein (hsCRP), hs-interleukin-6 (hsIL-6), and adiponectin were measured. RESULTS - Unadjusted PBMC CD36 mRNA and protein were 1.56- and 1.63-fold higher, respectively, among type 2 diabetic subjects versus control subjects. PBMC CD36 protein was directly associated with CD36 mRNA, plasma hsCRP, and hsIL-6 and inversely associated with plasma adiponectin in both groups. CONCLUSIONS - Increased CD36 expression is a biomarker of PBMC activation and inflammation and may become a useful tool in cardiovascular disease risk stratification.",

author = "Yijuan Sun and Marina Scavini and Orlando, {Robert A.} and Murata, {Glen H.} and Servilla, {Karen S.} and Tzamaloukas, {Antonios H.} and Ronald Schrader and Bedrick, {Edward J.} and Burge, {Mark R.} and Abumrad, {Nada A.} and Zager, {Philip G.}",

year = "2010",

month = sep,

doi = "10.2337/dc10-0460",

language = "English (US)",

volume = "33",

pages = "2065--2067",

journal = "Diabetes care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

number = "9",

}

TY - JOUR

T1 - Increased CD36 expression signals monocyte activation among patients with type 2 diabetes

AU - Sun, Yijuan

AU - Scavini, Marina

AU - Orlando, Robert A.

AU - Murata, Glen H.

AU - Servilla, Karen S.

AU - Tzamaloukas, Antonios H.

AU - Schrader, Ronald

AU - Bedrick, Edward J.

AU - Burge, Mark R.

AU - Abumrad, Nada A.

AU - Zager, Philip G.

PY - 2010/9

Y1 - 2010/9

N2 - OBJECTIVE - To explore the hypothesis that CD36, a scavenger receptor and fatty acid translocase, is upregulated in peripheral blood mononuclear cells (PBMCs) among patients with type 2 diabetes and is a biomarker of PBMC activation and inflammation. RESEARCH DESIGN AND METHODS - We used a cross-sectional observational design to study a multi-racial/ethnic population sample consisting of Caucasians, Hispanics, and Native Americans with type 2 diabetes (n = 33) and nondiabetic control subjects (n = 27). PBMC CD36 mRNA/protein and plasma high sensitivity (hs) C-reactive protein (hsCRP), hs-interleukin-6 (hsIL-6), and adiponectin were measured. RESULTS - Unadjusted PBMC CD36 mRNA and protein were 1.56- and 1.63-fold higher, respectively, among type 2 diabetic subjects versus control subjects. PBMC CD36 protein was directly associated with CD36 mRNA, plasma hsCRP, and hsIL-6 and inversely associated with plasma adiponectin in both groups. CONCLUSIONS - Increased CD36 expression is a biomarker of PBMC activation and inflammation and may become a useful tool in cardiovascular disease risk stratification.

AB - OBJECTIVE - To explore the hypothesis that CD36, a scavenger receptor and fatty acid translocase, is upregulated in peripheral blood mononuclear cells (PBMCs) among patients with type 2 diabetes and is a biomarker of PBMC activation and inflammation. RESEARCH DESIGN AND METHODS - We used a cross-sectional observational design to study a multi-racial/ethnic population sample consisting of Caucasians, Hispanics, and Native Americans with type 2 diabetes (n = 33) and nondiabetic control subjects (n = 27). PBMC CD36 mRNA/protein and plasma high sensitivity (hs) C-reactive protein (hsCRP), hs-interleukin-6 (hsIL-6), and adiponectin were measured. RESULTS - Unadjusted PBMC CD36 mRNA and protein were 1.56- and 1.63-fold higher, respectively, among type 2 diabetic subjects versus control subjects. PBMC CD36 protein was directly associated with CD36 mRNA, plasma hsCRP, and hsIL-6 and inversely associated with plasma adiponectin in both groups. CONCLUSIONS - Increased CD36 expression is a biomarker of PBMC activation and inflammation and may become a useful tool in cardiovascular disease risk stratification.

UR - http://www.scopus.com/inward/record.url?scp=79951658289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951658289&partnerID=8YFLogxK

U2 - 10.2337/dc10-0460

DO - 10.2337/dc10-0460

M3 - Article

C2 - 20551015

AN - SCOPUS:79951658289

SN - 0149-5992

VL - 33

SP - 2065

EP - 2067

JO - Diabetes care

JF - Diabetes care

IS - 9

ER -

Increased CD36 expression signals monocyte activation among patients with type 2 diabetes

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this